In recent research, scientists have discovered that blood vessels feeding high-grade glioma brain tumors have high levels of LDL receptors (LDLR) on them. The study found that using drug-containing nanoparticle-based therapies to target these receptors can be a new way of treating cancer. Gliomas are the most common primary brain tumors and, due to their highly aggressive nature, have a poor prognosis with an average survival of only 4.6 months without treatment and approximately 14 months with optimal multimodal treatments. This research could pave the way for treating glioma brain tumors with LDL receptor-targeted nanoparticle-based therapies, thereby cutting off the energy supply of cancer cells.